Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Sarcoma 2Head & Neck 2Breast 2Other solid neoplasm 1Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasms by Site 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × patritumab × Head & Neck × Clear all
NCT02633800 2019-01-07

Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

Daiichi Sankyo

Phase 2 Terminated
87 enrolled 13 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms by Site

NCT02350712 2018-09-11

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Daiichi Sankyo

Phase 1 Completed
15 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡